Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis

Epilepsy and Behavior

Volumn 25, Issue 1, 2012, Pages 92-97

  Samba Reddy, Doodipala ^a   Ramanathan, G ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

Author keywords

Epileptogenesis; Finasteride; Kindling; Neurosteroid; Progesterone; Seizure

Indexed keywords

ANTICONVULSIVE AGENT; FINASTERIDE; PROGESTERONE;

ANTICONVULSANT ACTIVITY; ARTICLE; EPILEPTOGENESIS; HIPPOCAMPUS; LIMBIC CORTEX;

5-ALPHA REDUCTASE INHIBITORS; ANIMALS; ANTICONVULSANTS; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ELECTRIC STIMULATION; EPILEPSY; FEMALE; FINASTERIDE; HIPPOCAMPUS; KINDLING, NEUROLOGIC; MICE; MICE, INBRED C57BL; PROGESTERONE; STATISTICS, NONPARAMETRIC;

EID: 84866299415     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2012.05.024     Document Type: Article

References (51)

1. Pitkänen A., Immonen R.J., Gröhn O.H., Kharatishvili I. From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options. Epilepsia 2009, 50(Suppl. 2):21-29.
2. Reddy D.S., Mohan A. Development and persistence of limbic epileptogenesis are impaired in mice lacking progesterone receptors. J Neurosci 2011, 31:650-658.
3. Herzog A.G., Fowler K.M. Sensitivity and specificity of the association between catamenial seizure patterns and ovulation. Neurology 2008, 70:486-487. The NIH Progesterone Trial Study Group.
4. Pack A.M., Reddy D.S., Duncan S., Herzog A. Neuroendocrinological aspects of epilepsy: important issues and trends in future research. Epilepsy Behav 2011, 22:94-102.
5. Craig C.R. Anticonvulsant activity of steroids: separability of anticonvulsant from hormonal effects. J Pharmacol Exp Ther 1966, 153:337-343.
6. Kokate T.G., Banks M.K., Magee T., Yamaguchi S., Rogawski M.A. Finasteride, a 5α-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 1999, 288:679-684.
7. Reddy D.S., Castenada D.A., O'Malley B.W., Rogawski M.A. Antiseizure activity of progesterone and neurosteroids in progesterone receptor knockout mice. J Pharmacol Exp Ther 2004, 310:230-239.
8. Bäckström T., Zetterlund B., Blom S., Romano M. Effect of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy. Acta Neurol Scand 1984, 69:240-248.
9. Herzog A.G. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology 1995, 45:1600-1662.
10. Herzog A.G. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology 1999, 52:1917-1918.
11. Herzog A.G., Fowler K.M., Smithson S.D. Progesterone versus placebo therapy for women with epilepsy: a randomized clinical trial. Neurology 2012, 78:1959-1966. The Progesterone Trial Study Group.
12. Herzog A.G., Klein P., Ransil B.J. Three patterns of catamenial epilepsy. Epilepsia 1997, 38:1082-1088.
13. Reddy D.S. The role of neurosteroids in the pathophysiology and treatment of catamenial epilepsy. Epilepsy Res 2009, 85:1-30.
14. Frye C.A., Rhodes M.E., Walf A., Harney J. Progesterone reduces pentylenetetrazol-induced ictal activity of wild-type mice but not those deficient in type I 5α-reductase. Epilepsia 2002, 43(Suppl. 5):14-17.
15. Lonsdale D., Burnham W.M. The anticonvulsant effects of progesterone and 5α-dihydroprogesterone on amygdala-kindled seizures in rats. Epilepsia 2003, 44:1494-1499.
16. Do Rego J.L., Seong J.Y., Burel D., et al. Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front Neuroendocrinol 2009, 30:259-301.
17. Herd M.B., Belelli D., Lambert J.J. Neurosteroid modulation of synaptic and extrasynaptic GABA-A receptors. Pharmacol Ther 2007, 116:20-34.
18. Wohlfarth K.M., Bianchi M.T., Macdonald R.L. Enhanced neurosteroid potentiation of ternary GABA-A receptors containing the delta subunit. J Neurosci 2002, 22:1541-1549.
19. Reddy D.S. Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy. Front Endocrinol 2011, 2:1-11. [article 38].
20. Belelli D., Bolger M.B., Gee K.W. Anticonvulsant profile of the progesterone metabolite 5α-pregnan-3α-ol-20-one. Eur J Pharmacol 1989, 166:325-329.
21. Kokate T.G., Svensson B.E., Rogawski M.A. Anticonvulsant activity of neurosteroids: correlation with gamma-aminobutyric acid-evoked chloride current potentiation. J Pharmacol Exp Ther 1994, 270:1223-1229.
22. Kaminski R.M., Livingood M.R., Rogawski M.A. Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 2004, 45:864-867.
23. Reddy D.S., Rogawski M.A. Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself. J Pharmacol Exp Ther 2000, 295:1241-1248.
24. Reddy D.S. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3α-androstanediol and 17β-estradiol. Neuroscience 2004, 129:195-207.
25. Reddy D.S., Rogawski M.A. Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA-A receptor function and seizure susceptibility. J Neurosci 2002, 22:3795-3805.
26. Edwards H.E., Mo V., Burnham W.M., MacLusky N.J. Gonadectomy unmasks an inhibitory effect of progesterone on amygdala kindling in male rats. Brain Res 2001, 889:260-263.
27. Reddy D.S., Gangisetty O., Briyal S. Disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis. Neuropharmacology 2010, 59:573-581.
28. Biagini G., Longo D., Baldelli E., et al. Neurosteroids and epileptogenesis in the pilocarpine model: evidence for a relationship between P450scc induction and length of the latent period. Epilepsia 2009, 50(Suppl. 1):53-58.
29. Biagini G., Baldelli E., Longo D., et al. Endogenous neurosteroids modulate epileptogenesis in a model of temporal lobe epilepsy. Exp Neurol 2006, 201:519-524.
30. Morimoto K., Fahnestock M., Racine R.J. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004, 73:1-60.
31. Racine R.J. Modification of seizure activity by electric stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 1972, 32:281-294.
32. Azzolina B., Ellsworth K., Andersson S., Geissler W., Bull H.G., Harris G.S. Inhibition of rat 5α-reductases by finasteride: evidence for isozyme differences in mechanism of inhibition. J Steroid Biochem Mol Biol 1997, 61:55-64.
33. Steiner J.F. Finasteride: a 5 alpha-reductase inhibitor. Clin Pharm 1993, 12:15-23.
34. Melcangi R.C., Poletti A., Cavarretta I., et al. The 5α-reductase in the central nervous system: expression and modes of control. J Steroid Biochem Mol Biol 1998, 65:295-299.
35. Finn D.A., Beadles-Bohling A.S., Beckley E.H., et al. A new look at the 5α-reductase inhibitor finasteride. CNS Drug Rev 2006, 12:53-76.
36. Paba S., Frau R., Godar S.C., Devoto P., Marrosu F., Bortolato M. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Curr Pharm Des 2011, 17:151-167.
37. Gangisetty O., Reddy D.S. Neurosteroid withdrawal regulates GABA-A receptor α4-subunit expression and seizure susceptibility by activation of progesterone receptor-independent early growth response factor-3 pathway. Neuroscience 2010, 170:865-880.
38. Reddy D.S., Gould J., Gangisetty O. A mouse kindling model of perimenstrual catamenial epilepsy. J Pharmacol Exp Ther 2012, 341:784-793.
39. Dusková M., Hill M., Hanus M., Matousková M., Stárka L. Finasteride treatment and neuroactive steroid formation. Prague Med Rep 2009, 110:222-230.
40. Brandt C., Glien M., Gastens A.M., et al. Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. Neuropharmacology 2007, 53:207-221.
41. Stein D.G., Sayeed I. Is progesterone worth consideration as a treatment for brain injury?. Am J Roentgenol 2010, 194:20-22.
42. Shen H., Sabaliauskas N., Sherpa A., et al. A critical role for α4βδ GABA-A receptors in shaping learning deficits at puberty in mice. Science 2010, 327(5972):1515-1518.
43. Wahnschaffe U., Löscher W. Lack of changes in seizure susceptibility during the estrous cycle in kindled rats. Epilepsy Res 1992, 13:199-204.
44. Edwards H.E., Burnham W.M., Ng M.M., Asa S., MacLusky N.J. Limbic seizures alter reproductive function in the female rat. Epilepsia 1999, 40:1370-1377.
45. Rupprecht R., Papadopoulos V., Rammes G., et al. Translocator protein (18kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010, 9:971-988.
46. Maguire J.L., Stell B.M., Rafizadeh M., Mody I. Ovarian cycle-linked changes in GABA-A receptors mediating tonic inhibition alter seizure susceptibility and anxiety. Nat Neurosci 2005, 8:797-804.
47. Gangisetty O., Reddy D.S. Ovarian cycle-related neurosteroid regulation of GABA-A receptor subunit plasticity in the hippocampus subfields. FASEB J 2011, [lb410, Suppl.].
48. Reddy D.S. Gender differences in antiseizure sensitivity of neurosteroids in the pilocarpine model of status epilepticus. Epilepsia 2009, 50(Suppl. 11):126.
49. Gorin-Meyer R.E., Wiren K.M., Tanchuck M.A., Long S.L., Yoneyama N., Finn D.A. Sex differences in the effect of finasteride on acute ethanol withdrawal severity in C57BL/6J and DBA/2J mice. Neuroscience 2007, 146:1302-1315.
50. Lawrence C., Martin B.S., Sun C., Williamson J., Kapur J. Endogenous neurosteroid synthesis modulates seizure frequency. Ann Neurol 2010, 67:689-693.
51. Herzog A.G., Frye C.A. Seizure exacerbation associated with inhibition of progesterone metabolism. Ann Neurol 2003, 53:390-391.